Form 4: Crinetics Pharmaceuticals Executive Sells Shares After Option Exercise
SEC Form 4 Filing
Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, sold 14,375 shares of common stock after exercising stock options at a lower price.
Summary
- On April 15, 2024, Dana Pizzuti, the Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options to acquire 14,375 shares of common stock at $16.89 per share.
- Simultaneously, Pizzuti sold 14,375 shares in the open market at a volume-weighted average price of $44.47 per share, with prices ranging from $43.98 to $44.75.
- Following these transactions, Pizzuti directly owns 27,786 shares of Crinetics Pharmaceuticals common stock.
- Pizzuti also directly owns options to purchase 177,292 shares of common stock.
- The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Comparison to Industry Standards
- Executive compensation packages often include stock options as incentives.
- The use of Rule 10b5-1 trading plans is a common practice among corporate executives to avoid accusations of insider trading.
- The difference between the exercise price and the sale price represents a profit for the executive, which is a typical outcome of stock option grants.
Stakeholder Impact
- The sale of shares by an executive could be perceived neutrally or slightly negatively by shareholders, depending on their interpretation of the executive's motives.
Key Dates
| Date | Description |
|---|---|
| 09/30/2023 | 25% of the shares subject to the option vest |
| 04/15/2024 | Date of transaction: exercise of stock options and sale of shares. |
| 04/17/2024 | Date of signature on the Form 4 filing. |
| 10/10/2032 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.